Fulgent Genetics (FLGT) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month target prices for Fulgent Genetics' stock. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they predict the company's share price to reach $42.33 in the next year. This suggests a possible upside of 7.6% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.

Fulgent Genetics' stock was trading at $29.78 at the beginning of the year. Since then, FLGT shares have increased by 32.1% and is now trading at $39.34.
View the best growth stocks for 2023 here.

Fulgent Genetics saw a increase in short interest in May. As of May 15th, there was short interest totaling 809,500 shares, an increase of 7.3% from the April 30th total of 754,300 shares. Based on an average daily trading volume, of 229,700 shares, the short-interest ratio is currently 3.5 days. Currently, 4.1% of the shares of the stock are sold short.
View Fulgent Genetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our FLGT earnings forecast.

Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its quarterly earnings data on Friday, May, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.21. The firm had revenue of $66.17 million for the quarter, compared to analyst estimates of $61.95 million. Fulgent Genetics had a negative net margin of 7.10% and a negative trailing twelve-month return on equity of 1.05%.

ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH) and WisdomTree U.S. SmallCap Earnings Fund (EES).

Fulgent Genetics issued an update on its second quarter 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $62.00 million-$62.00 million, compared to the consensus revenue estimate of $60.31 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.28%), Dimensional Fund Advisors LP (2.87%), State Street Corp (2.69%), Geode Capital Management LLC (1.36%), JPMorgan Chase & Co. (1.15%) and American Century Companies Inc. (0.94%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $39.34.

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $1.17 billion and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($0.89) on an earnings per share basis.

The company employs 1,012 workers across the globe.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.